SBIR-STTR Award

Studies of Dna Methyltransferases
Award last edited on: 12/29/14

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$1,258,771
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Richard J Roberts

Company Information

New England Biolabs Inc (AKA: BIOHELIX~NEB)

240 County Road
Ipswich, MA 01938
   (978) 927-5054
   tinger@neb.com
   www.neb.com
Location: Single
Congr. District: 06
County: Essex

Phase I

Contract Number: 1R44GM105125-01
Start Date: 9/28/12    Completed: 3/27/13
Phase I year
2012
Phase I Amount
$256,651
This project takes advantage of a DNA sequencing technology newly developed by Pacific Biosciences called SMRT sequencing. In addition to providing the DNA base sequence, this approach also allows the detection of modified bases. DNA methyltransferases have traditionally been rather difficult to characterize and as a result, we do not currently know the accurate DNA recognition specificity of any DNA methyltransferases. In the case of those that form part of restriction-modification systems, it has always been assumed that they will have the same recognition specificity as the restriction enzyme. However, in some systems preliminary results indicated that this might not be so, and we now in a position to test that explicitly. A knowledge of the specificity will be key on many fronts. Firstly, in some cases it will allow these methyltransferases to become valuable commercial reagents. Secondly, we expect to discover novel DNA methyltransferases with properties that would make them suitable for specific applications. One such enzyme discovered very recently, is M.EcoGI, which appears to recognize all A residues in a sequence and convert them at very high efficiency to N6- methyladenine. The results of this project will also greatly enhance the value of the cloned restriction-modification systems that we have at New England Biolabs and will also help considerably in the functional annotation of newly determined DNA sequences. It is an ideal blend of academic and commercial research and therefore is especially suited for New England Biolabs.

Public Health Relevance:
This project will characterize a large number of DNA methyltransferase genes in terms of their DNA recognition sequences as well as the specific base modified. These methyltransferases, once characterized, can serve as useful research reagents and their characterization will also help to improve genome annotation, which can be especially important for bacterial pathogens.

Public Health Relevance Statement:
This project will characterize a large number of DNA methyltransferase genes in terms of their DNA recognition sequences as well as the specific base modified. These methyltransferases, once characterized, can serve as useful research reagents and their characterization will also help to improve genome annotation, which can be especially important for bacterial pathogens.

Project Terms:
base; Base Sequence; Bioinformatics; Detection; DNA; DNA Methyltransferase; DNA Modification Methylases; DNA Restriction-Modification Enzymes; DNA Sequence; Engineering; Enzyme Gene; Enzymes; Family; gene discovery; Genome; Goals; improved; Knowledge; Methylation; Methyltransferase; Methyltransferase Gene; New England; novel; pathogen; Phase; Plasmids; Positioning Attribute; Production; Promotor (Genetics); Property; Reagent; Research; restriction enzyme; Site; Specificity; System; Technology; Testing; Type II site-specific deoxyribonuclease; Work

Phase II

Contract Number: 4R44GM105125-02
Start Date: 9/28/12    Completed: 2/28/15
Phase II year
2013
(last award dollars: 2014)
Phase II Amount
$1,002,120

This project takes advantage of a DNA sequencing technology newly developed by Pacific Biosciences called SMRT sequencing. In addition to providing the DNA base sequence, this approach also allows the detection of modified bases. DNA methyltransferases have traditionally been rather difficult to characterize and as a result, we do not currently know the accurate DNA recognition specificity of any DNA methyltransferases. In the case of those that form part of restriction-modification systems, it has always been assumed that they will have the same recognition specificity as the restriction enzyme. However, in some systems preliminary results indicated that this might not be so, and we now in a position to test that explicitly. A knowledge of the specificity will be key on many fronts. Firstly, in some cases it will allow these methyltransferases to become valuable commercial reagents. Secondly, we expect to discover novel DNA methyltransferases with properties that would make them suitable for specific applications. One such enzyme discovered very recently, is M.EcoGI, which appears to recognize all A residues in a sequence and convert them at very high efficiency to N6- methyladenine. The results of this project will also greatly enhance the value of the cloned restriction-modification systems that we have at New England Biolabs and will also help considerably in the functional annotation of newly determined DNA sequences. It is an ideal blend of academic and commercial research and therefore is especially suited for New England Biolabs.

Public Health Relevance Statement:
This project will characterize a large number of DNA methyltransferase genes in terms of their DNA recognition sequences as well as the specific base modified. These methyltransferases, once characterized, can serve as useful research reagents and their characterization will also help to improve genome annotation, which can be especially important for bacterial pathogens.

Project Terms:
base; Base Sequence; Bioinformatics; Detection; DNA; DNA Methyltransferase; DNA Modification Methylases; DNA Restriction-Modification Enzymes; DNA Sequence; Engineering; Enzyme Gene; Enzymes; Family; gene discovery; genome annotation; Goals; improved; Knowledge; Methylation; Methyltransferase; Methyltransferase Gene; New England; novel; pathogen; Phase; Plasmids; Positioning Attribute; Production; Promotor (Genetics); Property; Reagent; Research; restriction enzyme; Site; Specificity; System; Technology; Testing; Type II site-specific deoxyribonuclease; Work